TY - JOUR A2 - 德卡瓦略，Mamede AU - Alanazy，穆罕默德H. AU - Muayqil，TAIM PY - 2019 DA - 2019年8月21日TI - 在使用新型口服抗凝血药对非瓣膜病中房颤相关性卒中实践的差异中风神经学家在沙特阿拉伯SP - 5373250 VL - 2019 AB - 临床试验已经表明，新型口服抗凝血剂（NOACs）是不劣于防止非瓣膜性fibrillation-（nvAF-）相关中风和全身性栓塞于华法林。然而，在这些试验中，NOACs引发被推迟了中风后的可变周期。在此，我们的目的是调查在沙特阿拉伯中风神经科医生非瓣膜性房颤相关性卒中后NOACs的早期开始变异。标准化的问卷电子形式分发到了所有的笔划神经学家和研究员在沙特阿拉伯。主要集中在NOACs的定时问卷的NVAF相关中风后启动，根据行程大小（小，中和大）和位置（前部或后部循环）。42个中风神经学家，谁进行了接触的三十六（85.7％），参与了此次调查。All participants would initiate NOACs in the first 3 days after a TIA; most of them initiate NOACs within 7 days after a small stroke, 4–14 days after a medium stroke, and ≥12 days after a large stroke, regardless of stroke location. Presence of a symptomatic intracranial hemorrhage further delayed initiation of NOACs. Additionally, 77.8% of the participants would bridge with antiplatelets before initiation of NOACs, and 55.6% would use a single antiplatelet agent. In conclusion, the practice of stroke neurologists is consistent with and supports the available evidence from observational studies on the time of initiation of NOACs. Our findings provide a guide for clinicians who manage nvAF-related stroke until more robust evidence from randomized controlled trials is available. SN - 2090-1852 UR - https://doi.org/10.1155/2019/5373250 DO - 10.1155/2019/5373250 JF - Neurology Research International PB - Hindawi KW - ER -